Publication & Citation Trends
Most Cited Works
Publications
217 total
Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group PDF
Cited by 431
OpenAlex
Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines PDF
Cited by 253
OpenAlex
Inhibition of Poly(ADP-Ribose) Polymerase Enhances Cell Death and Improves Tumor Growth Delay in Irradiated Lung Cancer Models
Cited by 263
OpenAlex
Pooled Analysis of Safety and Efficacy of Oxaliplatin Plus Fluorouracil/Leucovorin Administered Bimonthly in Elderly Patients With Colorectal Cancer
Cited by 468
OpenAlex
Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial
Cited by 644
OpenAlex
Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial
Cited by 578
OpenAlex
Research Topics
Colorectal Cancer Treatments and Studies
(71)
Cancer Treatment and Pharmacology
(53)
Cancer therapeutics and mechanisms
(50)
Lung Cancer Treatments and Mutations
(36)
Cancer Genomics and Diagnostics
(28)
Frequent Co-Authors
Affiliations
Rutgers, The State University of New Jersey
Northwestern University
Ontario Institute for Cancer Research
Gynecologic Oncology Group
Brigham and Women's Hospital